Skip to main content
Molecular Pathology : MP logoLink to Molecular Pathology : MP
. 1997 Dec;50(6):281–288. doi: 10.1136/mp.50.6.281

Genetic prognostic markers in colorectal cancer.

R S Houlston 1, I P Tomlinson 1
PMCID: PMC379660  PMID: 9536276

Abstract

The contribution of molecular genetics to colorectal cancer has been restricted largely to relatively rare inherited tumours and to the detection of germline mutations predisposing to these cancers. However, much is now also known about somatic events leading to colorectal cancer. A number of studies has been undertaken examining possible relations between genetic features and prognostic indices. While many of these studies are small and inconclusive, it is clear that a number of different pathways exist for the development of this cancer and some molecular characteristics correlate with clinicopathological features. With the advent of methods for the rapid genotyping of large numbers of colorectal cancers, it should be possible to evaluate fully the clinical usefulness of colorectal cancer genotypes through multivariate analyses.

Full text

PDF
283

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaltonen L. A., Peltomäki P., Leach F. S., Sistonen P., Pylkkänen L., Mecklin J. P., Järvinen H., Powell S. M., Jen J., Hamilton S. R. Clues to the pathogenesis of familial colorectal cancer. Science. 1993 May 7;260(5109):812–816. doi: 10.1126/science.8484121. [DOI] [PubMed] [Google Scholar]
  2. Baeg G. H., Matsumine A., Kuroda T., Bhattacharjee R. N., Miyashiro I., Toyoshima K., Akiyama T. The tumour suppressor gene product APC blocks cell cycle progression from G0/G1 to S phase. EMBO J. 1995 Nov 15;14(22):5618–5625. doi: 10.1002/j.1460-2075.1995.tb00249.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baker S. J., Preisinger A. C., Jessup J. M., Paraskeva C., Markowitz S., Willson J. K., Hamilton S., Vogelstein B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990 Dec 1;50(23):7717–7722. [PubMed] [Google Scholar]
  4. Beart R. W., Steele G. D., Jr, Menck H. R., Chmiel J. S., Ocwieja K. E., Winchester D. P. Management and survival of patients with adenocarcinoma of the colon and rectum: a national survey of the Commission on Cancer. J Am Coll Surg. 1995 Sep;181(3):225–236. [PubMed] [Google Scholar]
  5. Bell S. M., Scott N., Cross D., Sagar P., Lewis F. A., Blair G. E., Taylor G. R., Dixon M. F., Quirke P. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 1993 Jan;104(1):57–64. doi: 10.1016/0016-5085(93)90835-z. [DOI] [PubMed] [Google Scholar]
  6. Benhattar J., Losi L., Chaubert P., Givel J. C., Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology. 1993 Apr;104(4):1044–1048. doi: 10.1016/0016-5085(93)90272-e. [DOI] [PubMed] [Google Scholar]
  7. Bertorelle R., Esposito G., Del Mistro A., Belluco C., Nitti D., Lise M., Chieco-Bianchi L. Association of p53 gene and protein alterations with metastases in colorectal cancer. Am J Surg Pathol. 1995 Apr;19(4):463–471. doi: 10.1097/00000478-199504000-00008. [DOI] [PubMed] [Google Scholar]
  8. Bird R. P. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett. 1995 Jun 29;93(1):55–71. doi: 10.1016/0304-3835(95)03788-X. [DOI] [PubMed] [Google Scholar]
  9. Bos J. L. The ras gene family and human carcinogenesis. Mutat Res. 1988 May;195(3):255–271. doi: 10.1016/0165-1110(88)90004-8. [DOI] [PubMed] [Google Scholar]
  10. Bos J. L., Toksoz D., Marshall C. J., Verlaan-de Vries M., Veeneman G. H., van der Eb A. J., van Boom J. H., Janssen J. W., Steenvoorden A. C. Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. 1985 Jun 27-Jul 3Nature. 315(6022):726–730. doi: 10.1038/315726a0. [DOI] [PubMed] [Google Scholar]
  11. Bosari S., Viale G., Roncalli M., Graziani D., Borsani G., Lee A. K., Coggi G. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol. 1995 Sep;147(3):790–798. [PMC free article] [PubMed] [Google Scholar]
  12. Brentnall T. A., Crispin D. A., Rabinovitch P. S., Haggitt R. C., Rubin C. E., Stevens A. C., Burmer G. C. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994 Aug;107(2):369–378. doi: 10.1016/0016-5085(94)90161-9. [DOI] [PubMed] [Google Scholar]
  13. Browne S. J., Williams A. C., Hague A., Butt A. J., Paraskeva C. Loss of APC protein expressed by human colonic epithelial cells and the appearance of a specific low-molecular-weight form is associated with apoptosis in vitro. Int J Cancer. 1994 Oct 1;59(1):56–64. doi: 10.1002/ijc.2910590113. [DOI] [PubMed] [Google Scholar]
  14. Bubb V. J., Curtis L. J., Cunningham C., Dunlop M. G., Carothers A. D., Morris R. G., White S., Bird C. C., Wyllie A. H. Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer. Oncogene. 1996 Jun 20;12(12):2641–2649. [PubMed] [Google Scholar]
  15. Burchill S. A. The tumour suppressor APC gene product is associated with cell adhesion. Bioessays. 1994 Apr;16(4):225–227. doi: 10.1002/bies.950160403. [DOI] [PubMed] [Google Scholar]
  16. Campo E., Miquel R., Jares P., Bosch F., Juan M., Leone A., Vives J., Cardesa A., Yague J. Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal carcinomas. Cancer. 1994 Jun 15;73(12):2913–2921. doi: 10.1002/1097-0142(19940615)73:12<2913::aid-cncr2820731207>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  17. Carder P., Wyllie A. H., Purdie C. A., Morris R. G., White S., Piris J., Bird C. C. Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene. 1993 May;8(5):1397–1401. [PubMed] [Google Scholar]
  18. Cawkwell L., Lewis F. A., Quirke P. Frequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. Br J Cancer. 1994 Nov;70(5):813–818. doi: 10.1038/bjc.1994.404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Cohn K. H., Ornstein D. L., Wang F., LaPaix F. D., Phipps K., Edelsberg C., Zuna R., Mott L. A., Dunn J. L. The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5-year follow-up study. Cancer. 1997 Jan 15;79(2):233–244. [PubMed] [Google Scholar]
  20. Connell W. R., Talbot I. C., Harpaz N., Britto N., Wilkinson K. H., Kamm M. A., Lennard-Jones J. E. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut. 1994 Oct;35(10):1419–1423. doi: 10.1136/gut.35.10.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Cunningham C., Dunlop M. G., Wyllie A. H., Bird C. C. Deletion mapping in colorectal cancer of a putative tumour suppressor gene in 8p22-p21.3. Oncogene. 1993 May;8(5):1391–1396. [PubMed] [Google Scholar]
  22. Cunningham J., Lust J. A., Schaid D. J., Bren G. D., Carpenter H. A., Rizza E., Kovach J. S., Thibodeau S. N. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res. 1992 Apr 1;52(7):1974–1980. [PubMed] [Google Scholar]
  23. Curtis L. J., Bubb V. J., Gledhill S., Morris R. G., Bird C. C., Wyllie A. H. Loss of heterozygosity of MCC is not associated with mutation of the retained allele in sporadic colorectal cancer. Hum Mol Genet. 1994 Mar;3(3):443–446. doi: 10.1093/hmg/3.3.443. [DOI] [PubMed] [Google Scholar]
  24. DUKES C. E., BUSSEY H. J. The spread of rectal cancer and its effect on prognosis. Br J Cancer. 1958 Sep;12(3):309–320. doi: 10.1038/bjc.1958.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Der C. J., Finkel T., Cooper G. M. Biological and biochemical properties of human rasH genes mutated at codon 61. Cell. 1986 Jan 17;44(1):167–176. doi: 10.1016/0092-8674(86)90495-2. [DOI] [PubMed] [Google Scholar]
  26. Diez M., Enriquez J. M., Camuñas J., Gonzalez A., Gutierrez A., Mugüerza J. M., Ruiz A., Granell J. Prediction of recurrence in B-C stages of colorectal cancer by p53 nuclear overexpression in comparison with standard pathological features. Eur J Surg Oncol. 1995 Dec;21(6):635–639. doi: 10.1016/s0748-7983(95)95477-5. [DOI] [PubMed] [Google Scholar]
  27. Donehower L. A., Bradley A. The tumor suppressor p53. Biochim Biophys Acta. 1993 Aug 23;1155(2):181–205. doi: 10.1016/0304-419x(93)90004-v. [DOI] [PubMed] [Google Scholar]
  28. Fasano O., Aldrich T., Tamanoi F., Taparowsky E., Furth M., Wigler M. Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proc Natl Acad Sci U S A. 1984 Jul;81(13):4008–4012. doi: 10.1073/pnas.81.13.4008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. doi: 10.1016/0092-8674(90)90186-i. [DOI] [PubMed] [Google Scholar]
  30. Finkelstein S. D., Sayegh R., Christensen S., Swalsky P. A. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer. 1993 Jun 15;71(12):3827–3838. doi: 10.1002/1097-0142(19930615)71:12<3827::aid-cncr2820711207>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  31. Fishel R., Lescoe M. K., Rao M. R., Copeland N. G., Jenkins N. A., Garber J., Kane M., Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993 Dec 3;75(5):1027–1038. doi: 10.1016/0092-8674(93)90546-3. [DOI] [PubMed] [Google Scholar]
  32. Fujita S., Moriya Y., Sugihara K., Akasu T., Ushio K. Prognosis of hereditary nonpolyposis colorectal cancer (HNPCC) and the role of Japanese criteria for HNPCC. Jpn J Clin Oncol. 1996 Oct;26(5):351–355. doi: 10.1093/oxfordjournals.jjco.a023244. [DOI] [PubMed] [Google Scholar]
  33. Fujiwara Y., Emi M., Ohata H., Kato Y., Nakajima T., Mori T., Nakamura Y. Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res. 1993 Mar 1;53(5):1172–1174. [PubMed] [Google Scholar]
  34. Gerdes H., Chen Q., Elahi A. H., Sircar A., Goldberg E., Winawer D., Urmacher C., Winawer S. J., Jhanwar S. C. Recurrent deletions involving chromosomes 1, 5, 17, and 18 in colorectal carcinoma: possible role in biological and clinical behavior of tumors. Anticancer Res. 1995 Jan-Feb;15(1):13–24. [PubMed] [Google Scholar]
  35. Giardiello F. M. Sulindac and polyp regression. Cancer Metastasis Rev. 1994 Dec;13(3-4):279–283. doi: 10.1007/BF00666098. [DOI] [PubMed] [Google Scholar]
  36. Goh H. S., Chan C. S., Khine K., Smith D. R. p53 and behaviour of colorectal cancer. Lancet. 1994 Jul 23;344(8917):233–234. doi: 10.1016/s0140-6736(94)93000-7. [DOI] [PubMed] [Google Scholar]
  37. Goh H. S., Yao J., Smith D. R. p53 point mutation and survival in colorectal cancer patients. Cancer Res. 1995 Nov 15;55(22):5217–5221. [PubMed] [Google Scholar]
  38. Gonzalez-Zulueta M., Bender C. M., Yang A. S., Nguyen T., Beart R. W., Van Tornout J. M., Jones P. A. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995 Oct 15;55(20):4531–4535. [PubMed] [Google Scholar]
  39. Grewal H., Guillem J. G., Klimstra D. S., Cohen A. M. p53 nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. Dis Colon Rectum. 1995 Nov;38(11):1176–1181. doi: 10.1007/BF02048333. [DOI] [PubMed] [Google Scholar]
  40. Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertsen H., Joslyn G., Stevens J., Spirio L., Robertson M. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991 Aug 9;66(3):589–600. doi: 10.1016/0092-8674(81)90021-0. [DOI] [PubMed] [Google Scholar]
  41. Gustafson C. E., Young J., Leggett B., Searle J., Chenevix-Trench G. Loss of heterozygosity on the long arm of chromosome 11 in colorectal tumours. Br J Cancer. 1994 Sep;70(3):395–397. doi: 10.1038/bjc.1994.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Hahn S. A., Hoque A. T., Moskaluk C. A., da Costa L. T., Schutte M., Rozenblum E., Seymour A. B., Weinstein C. L., Yeo C. J., Hruban R. H. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. 1996 Feb 1;56(3):490–494. [PubMed] [Google Scholar]
  43. Hamelin R., Laurent-Puig P., Olschwang S., Jego N., Asselain B., Remvikos Y., Girodet J., Salmon R. J., Thomas G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology. 1994 Jan;106(1):42–48. doi: 10.1016/s0016-5085(94)94217-x. [DOI] [PubMed] [Google Scholar]
  44. Hemminki A., Tomlinson I., Markie D., Järvinen H., Sistonen P., Björkqvist A. M., Knuutila S., Salovaara R., Bodmer W., Shibata D. Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet. 1997 Jan;15(1):87–90. doi: 10.1038/ng0197-87. [DOI] [PubMed] [Google Scholar]
  45. Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J. P., Davidson N. E., Sidransky D., Baylin S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995 Oct 15;55(20):4525–4530. [PubMed] [Google Scholar]
  46. Houbiers J. G., van der Burg S. H., van de Watering L. M., Tollenaar R. A., Brand A., van de Velde C. J., Melief C. J. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer. 1995 Sep;72(3):637–641. doi: 10.1038/bjc.1995.386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Iacopetta B., DiGrandi S., Dix B., Haig C., Soong R., House A. Loss of heterozygosity of tumour suppressor gene loci in human colorectal carcinoma. Eur J Cancer. 1994;30A(5):664–670. doi: 10.1016/0959-8049(94)90541-x. [DOI] [PubMed] [Google Scholar]
  48. Ichikawa W. Positive relationship between expression of CD44 and hepatic metastases in colorectal cancer. Pathobiology. 1994;62(4):172–179. doi: 10.1159/000163907. [DOI] [PubMed] [Google Scholar]
  49. Ilyas M., Tomlinson I. P. Genetic pathways in colorectal cancer. Histopathology. 1996 May;28(5):389–399. doi: 10.1046/j.1365-2559.1996.339381.x. [DOI] [PubMed] [Google Scholar]
  50. Ilyas M., Tomlinson I. P., Novelli M. R., Hanby A., Bodmer W. F., Talbot I. C. Clinico-pathological features and p53 expression in left-sided sporadic colorectal cancers with and without microsatellite instability. J Pathol. 1996 Aug;179(4):370–375. doi: 10.1002/(SICI)1096-9896(199608)179:4<370::AID-PATH627>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  51. Ishimaru G., Adachi J., Shiseki M., Yamaguchi N., Muto T., Yokota J. Microsatellite instability in primary and metastatic colorectal cancers. Int J Cancer. 1995 Jun 22;64(3):153–157. doi: 10.1002/ijc.2910640302. [DOI] [PubMed] [Google Scholar]
  52. Jeevaratnam P., Cottier D. S., Browett P. J., Van De Water N. S., Pokos V., Jass J. R. Familial giant hyperplastic polyposis predisposing to colorectal cancer: a new hereditary bowel cancer syndrome. J Pathol. 1996 May;179(1):20–25. doi: 10.1002/(SICI)1096-9896(199605)179:1<20::AID-PATH538>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  53. Jen J., Kim H., Piantadosi S., Liu Z. F., Levitt R. C., Sistonen P., Kinzler K. W., Vogelstein B., Hamilton S. R. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994 Jul 28;331(4):213–221. doi: 10.1056/NEJM199407283310401. [DOI] [PubMed] [Google Scholar]
  54. Joslyn G., Richardson D. S., White R., Alber T. Dimer formation by an N-terminal coiled coil in the APC protein. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11109–11113. doi: 10.1073/pnas.90.23.11109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Kastrinakis W. V., Ramchurren N., Maggard M., Steele G., Jr, Summerhayes I. C. K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch Surg. 1995 Jan;130(1):9–14. doi: 10.1001/archsurg.1995.01430010011001. [DOI] [PubMed] [Google Scholar]
  56. Kastrinakis W. V., Ramchurren N., Rieger K. M., Hess D. T., Loda M., Steele G., Summerhayes I. C. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene. 1995 Aug 17;11(4):647–652. [PubMed] [Google Scholar]
  57. Kawasaki Y., Monden T., Morimoto H., Murotani M., Miyoshi Y., Kobayashi T., Shimano T., Mori T. Immunohistochemical study of p53 expression in microwave-fixed, paraffin-embedded sections of colorectal carcinoma and adenoma. Am J Clin Pathol. 1992 Feb;97(2):244–249. doi: 10.1093/ajcp/97.2.244. [DOI] [PubMed] [Google Scholar]
  58. Kelemen P. R., Yaremko M. L., Kim A. H., Montag A., Michelassi F., Westbrook C. A. Loss of heterozygosity in 8p is associated with microinvasion in colorectal carcinoma. Genes Chromosomes Cancer. 1994 Nov;11(3):195–198. doi: 10.1002/gcc.2870110308. [DOI] [PubMed] [Google Scholar]
  59. Kern S. E., Fearon E. R., Tersmette K. W., Enterline J. P., Leppert M., Nakamura Y., White R., Vogelstein B., Hamilton S. R. Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. JAMA. 1989 Jun 2;261(21):3099–3103. doi: 10.1001/jama.261.21.3099. [DOI] [PubMed] [Google Scholar]
  60. Khine K., Smith D. R., Goh H. S. High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer. Cancer. 1994 Jan 1;73(1):28–35. doi: 10.1002/1097-0142(19940101)73:1<28::aid-cncr2820730107>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  61. Kim H., Jen J., Vogelstein B., Hamilton S. R. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol. 1994 Jul;145(1):148–156. [PMC free article] [PubMed] [Google Scholar]
  62. Kinzler K. W., Nilbert M. C., Su L. K., Vogelstein B., Bryan T. M., Levy D. B., Smith K. J., Preisinger A. C., Hedge P., McKechnie D. Identification of FAP locus genes from chromosome 5q21. Science. 1991 Aug 9;253(5020):661–665. doi: 10.1126/science.1651562. [DOI] [PubMed] [Google Scholar]
  63. Kinzler K. W., Nilbert M. C., Vogelstein B., Bryan T. M., Levy D. B., Smith K. J., Preisinger A. C., Hamilton S. R., Hedge P., Markham A. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science. 1991 Mar 15;251(4999):1366–1370. doi: 10.1126/science.1848370. [DOI] [PubMed] [Google Scholar]
  64. Krawczak M., Smith-Sorensen B., Schmidtke J., Kakkar V. V., Cooper D. N., Hovig E. Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Hum Mutat. 1995;5(1):48–57. doi: 10.1002/humu.1380050107. [DOI] [PubMed] [Google Scholar]
  65. Kressner U., Lindmark G., Gerdin B., Påhlman L., Glimelius B. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res. 1996 Mar-Apr;16(2):951–957. [PubMed] [Google Scholar]
  66. Lane D. P. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
  67. Laurent-Puig P., Olschwang S., Delattre O., Remvikos Y., Asselain B., Melot T., Validire P., Muleris M., Girodet J., Salmon R. J. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology. 1992 Apr;102(4 Pt 1):1136–1141. [PubMed] [Google Scholar]
  68. Lazaris A. C., Theodoropoulos G. E., Anastassopoulos P., Nakopoulou L., Panoussopoulos D., Papadimitriou K. Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma. Histol Histopathol. 1995 Jul;10(3):661–668. [PubMed] [Google Scholar]
  69. Leach F. S., Nicolaides N. C., Papadopoulos N., Liu B., Jen J., Parsons R., Peltomäki P., Sistonen P., Aaltonen L. A., Nyström-Lahti M. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 1993 Dec 17;75(6):1215–1225. doi: 10.1016/0092-8674(93)90330-s. [DOI] [PubMed] [Google Scholar]
  70. Leister I., Weith A., Brüderlein S., Cziepluch C., Kangwanpong D., Schlag P., Schwab M. Human colorectal cancer: high frequency of deletions at chromosome 1p35. Cancer Res. 1990 Nov 15;50(22):7232–7235. [PubMed] [Google Scholar]
  71. Liaw D., Marsh D. J., Li J., Dahia P. L., Wang S. I., Zheng Z., Bose S., Call K. M., Tsou H. C., Peacocke M. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997 May;16(1):64–67. doi: 10.1038/ng0597-64. [DOI] [PubMed] [Google Scholar]
  72. Lindblom A., Tannergård P., Werelius B., Nordenskjöld M. Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet. 1993 Nov;5(3):279–282. doi: 10.1038/ng1193-279. [DOI] [PubMed] [Google Scholar]
  73. Linn S. C., Giaccone G. MDR1/P-glycoprotein expression in colorectal cancer. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1291–1294. doi: 10.1016/0959-8049(95)00278-q. [DOI] [PubMed] [Google Scholar]
  74. Liu B., Nicolaides N. C., Markowitz S., Willson J. K., Parsons R. E., Jen J., Papadopolous N., Peltomäki P., de la Chapelle A., Hamilton S. R. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet. 1995 Jan;9(1):48–55. doi: 10.1038/ng0195-48. [DOI] [PubMed] [Google Scholar]
  75. Liu B., Parsons R., Papadopoulos N., Nicolaides N. C., Lynch H. T., Watson P., Jass J. R., Dunlop M., Wyllie A., Peltomäki P. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med. 1996 Feb;2(2):169–174. doi: 10.1038/nm0296-169. [DOI] [PubMed] [Google Scholar]
  76. Loda M., Cukor B., Tam S. W., Lavin P., Fiorentino M., Draetta G. F., Jessup J. M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997 Feb;3(2):231–234. doi: 10.1038/nm0297-231. [DOI] [PubMed] [Google Scholar]
  77. MacDonald N. J., de la Rosa A., Steeg P. S. The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1096–1100. doi: 10.1016/0959-8049(95)00152-9. [DOI] [PubMed] [Google Scholar]
  78. Manne V., Bekesi E., Kung H. F. Ha-ras proteins exhibit GTPase activity: point mutations that activate Ha-ras gene products result in decreased GTPase activity. Proc Natl Acad Sci U S A. 1985 Jan;82(2):376–380. doi: 10.1073/pnas.82.2.376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Martinez J. A., Prevot S., Nordlinger B., Nguyen T. M., Lacarriere Y., Munier A., Lascu I., Vaillant J. C., Capeau J., Lacombe M. L. Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumour stages. Gut. 1995 Nov;37(5):712–720. doi: 10.1136/gut.37.5.712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. McGrath J. P., Capon D. J., Goeddel D. V., Levinson A. D. Comparative biochemical properties of normal and activated human ras p21 protein. Nature. 1984 Aug 23;310(5979):644–649. doi: 10.1038/310644a0. [DOI] [PubMed] [Google Scholar]
  81. Minamoto T., Yamashita N., Ochiai A., Mai M., Sugimura T., Ronai Z., Esumi H. Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis. Cancer. 1995 Mar 15;75(6 Suppl):1520–1526. doi: 10.1002/1097-0142(19950315)75:6+<1520::aid-cncr2820751523>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  82. Miyoshi Y., Nagase H., Ando H., Horii A., Ichii S., Nakatsuru S., Aoki T., Miki Y., Mori T., Nakamura Y. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet. 1992 Jul;1(4):229–233. doi: 10.1093/hmg/1.4.229. [DOI] [PubMed] [Google Scholar]
  83. Moerkerk P., Arends J. W., van Driel M., de Bruïne A., de Goeij A., ten Kate J. Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res. 1994 Jul 1;54(13):3376–3378. [PubMed] [Google Scholar]
  84. Morrin M., Kelly M., Barrett N., Delaney P. Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut. 1994 Nov;35(11):1627–1631. doi: 10.1136/gut.35.11.1627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Munemitsu S., Souza B., Müller O., Albert I., Rubinfeld B., Polakis P. The APC gene product associates with microtubules in vivo and promotes their assembly in vitro. Cancer Res. 1994 Jul 15;54(14):3676–3681. [PubMed] [Google Scholar]
  86. Nathanson S. D., Linden M. D., Tender P., Zarbo R. J., Jacobsen G., Nelson L. T. Relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum. 1994 Jun;37(6):527–534. doi: 10.1007/BF02050985. [DOI] [PubMed] [Google Scholar]
  87. Nuovo G. J. In situ PCR: protocols and applications. PCR Methods Appl. 1995 Feb;4(4):S151–S167. doi: 10.1101/gr.4.4.s151. [DOI] [PubMed] [Google Scholar]
  88. Ohta M., Inoue H., Cotticelli M. G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., McCue P., Druck T. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996 Feb 23;84(4):587–597. doi: 10.1016/s0092-8674(00)81034-x. [DOI] [PubMed] [Google Scholar]
  89. Okamoto A., Demetrick D. J., Spillare E. A., Hagiwara K., Hussain S. P., Bennett W. P., Forrester K., Gerwin B., Serrano M., Beach D. H. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11045–11049. doi: 10.1073/pnas.91.23.11045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Pignatelli M., Liu D., Nasim M. M., Stamp G. W., Hirano S., Takeichi M. Morphoregulatory activities of E-cadherin and beta-1 integrins in colorectal tumour cells. Br J Cancer. 1992 Oct;66(4):629–634. doi: 10.1038/bjc.1992.328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Powell S. M., Zilz N., Beazer-Barclay Y., Bryan T. M., Hamilton S. R., Thibodeau S. N., Vogelstein B., Kinzler K. W. APC mutations occur early during colorectal tumorigenesis. Nature. 1992 Sep 17;359(6392):235–237. doi: 10.1038/359235a0. [DOI] [PubMed] [Google Scholar]
  92. Praml C., Finke L. H., Herfarth C., Schlag P., Schwab M., Amler L. Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancer. Oncogene. 1995 Oct 5;11(7):1357–1362. [PubMed] [Google Scholar]
  93. Pretlow T. P. Aberrant crypt foci and K-ras mutations: earliest recognized players or innocent bystanders in colon carcinogenesis? Gastroenterology. 1995 Feb;108(2):600–603. doi: 10.1016/0016-5085(95)90092-6. [DOI] [PubMed] [Google Scholar]
  94. Pricolo V. E., Finkelstein S. D., Wu T. T., Keller G., Bakker A., Swalsky P. A., Bland K. I. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg. 1996 Jan;171(1):41–46. doi: 10.1016/S0002-9610(99)80071-3. [DOI] [PubMed] [Google Scholar]
  95. Purdie C. A., Piris J., Bird C. C., Wyllie A. H. 17q allele loss is associated with lymph node metastasis in locally aggressive human colorectal cancer. J Pathol. 1995 Mar;175(3):297–302. doi: 10.1002/path.1711750307. [DOI] [PubMed] [Google Scholar]
  96. Redston M. S., Papadopoulos N., Caldas C., Kinzler K. W., Kern S. E. Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology. 1995 Feb;108(2):383–392. doi: 10.1016/0016-5085(95)90064-0. [DOI] [PubMed] [Google Scholar]
  97. Remvikos Y., Tominaga O., Hammel P., Laurent-Puig P., Salmon R. J., Dutrillaux B., Thomas G. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer. 1992 Oct;66(4):758–764. doi: 10.1038/bjc.1992.352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Rubinfeld B., Souza B., Albert I., Müller O., Chamberlain S. H., Masiarz F. R., Munemitsu S., Polakis P. Association of the APC gene product with beta-catenin. Science. 1993 Dec 10;262(5140):1731–1734. doi: 10.1126/science.8259518. [DOI] [PubMed] [Google Scholar]
  99. Sankila R., Aaltonen L. A., Järvinen H. J., Mecklin J. P. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology. 1996 Mar;110(3):682–687. doi: 10.1053/gast.1996.v110.pm8608876. [DOI] [PubMed] [Google Scholar]
  100. Seeburg P. H., Colby W. W., Capon D. J., Goeddel D. V., Levinson A. D. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature. 1984 Nov 1;312(5989):71–75. doi: 10.1038/312071a0. [DOI] [PubMed] [Google Scholar]
  101. Shepherd J. A. Regression phenomenon in familial polyposis. Proc R Soc Med. 1972 Feb;65(2):169–169. [PMC free article] [PubMed] [Google Scholar]
  102. Shibata D., Reale M. A., Lavin P., Silverman M., Fearon E. R., Steele G., Jr, Jessup J. M., Loda M., Summerhayes I. C. The DCC protein and prognosis in colorectal cancer. N Engl J Med. 1996 Dec 5;335(23):1727–1732. doi: 10.1056/NEJM199612053352303. [DOI] [PubMed] [Google Scholar]
  103. Sier C. F., Vloedgraven H. J., Griffioen G., Ganesh S., Nagengast F. M., Lamers C. B., Verspaget H. W. Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. Br J Cancer. 1995 Feb;71(2):393–396. doi: 10.1038/bjc.1995.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Smith A. J., Stern H. S., Penner M., Hay K., Mitri A., Bapat B. V., Gallinger S. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res. 1994 Nov 1;54(21):5527–5530. [PubMed] [Google Scholar]
  105. Smith D. R., Ji C. Y., Goh H. S. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer. 1996 Jul;74(2):216–223. doi: 10.1038/bjc.1996.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Solomon E., Voss R., Hall V., Bodmer W. F., Jass J. R., Jeffreys A. J., Lucibello F. C., Patel I., Rider S. H. Chromosome 5 allele loss in human colorectal carcinomas. Nature. 1987 Aug 13;328(6131):616–619. doi: 10.1038/328616a0. [DOI] [PubMed] [Google Scholar]
  107. Span M., Moerkerk P. T., De Goeij A. F., Arends J. W. A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer. 1996 Jun 21;69(3):241–245. doi: 10.1002/(SICI)1097-0215(19960621)69:3<241::AID-IJC15>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  108. Steeg P. S., Abrams J. S. Cancer prognostics: past, present and p27. Nat Med. 1997 Feb;3(2):152–154. doi: 10.1038/nm0297-152. [DOI] [PubMed] [Google Scholar]
  109. Su L. K., Vogelstein B., Kinzler K. W. Association of the APC tumor suppressor protein with catenins. Science. 1993 Dec 10;262(5140):1734–1737. doi: 10.1126/science.8259519. [DOI] [PubMed] [Google Scholar]
  110. Tanaka M., Omura K., Watanabe Y., Oda Y., Nakanishi I. Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol. 1994 Sep;57(1):57–64. doi: 10.1002/jso.2930570115. [DOI] [PubMed] [Google Scholar]
  111. Tarmin L., Yin J., Harpaz N., Kozam M., Noordzij J., Antonio L. B., Jiang H. Y., Chan O., Cymes K., Meltzer S. J. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res. 1995 May 15;55(10):2035–2038. [PubMed] [Google Scholar]
  112. Tomlinson I. P., Novelli M. R., Bodmer W. F. The mutation rate and cancer. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14800–14803. doi: 10.1073/pnas.93.25.14800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Tomoda H., Kakeji Y. Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance. J Surg Oncol. 1995 Feb;58(2):125–128. doi: 10.1002/jso.2930580211. [DOI] [PubMed] [Google Scholar]
  114. Tops C. M., van der Klift H. M., van der Luijt R. B., Griffioen G., Taal B. G., Vasen H. F., Khan P. M. Non-allelic heterogeneity of familial adenomatous polyposis. Am J Med Genet. 1993 Sep 15;47(4):563–567. doi: 10.1002/ajmg.1320470425. [DOI] [PubMed] [Google Scholar]
  115. Vogelstein B., Fearon E. R., Hamilton S. R., Kern S. E., Preisinger A. C., Leppert M., Nakamura Y., White R., Smits A. M., Bos J. L. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988 Sep 1;319(9):525–532. doi: 10.1056/NEJM198809013190901. [DOI] [PubMed] [Google Scholar]
  116. Vogelstein B., Fearon E. R., Kern S. E., Hamilton S. R., Preisinger A. C., Nakamura Y., White R. Allelotype of colorectal carcinomas. Science. 1989 Apr 14;244(4901):207–211. doi: 10.1126/science.2565047. [DOI] [PubMed] [Google Scholar]
  117. Whitelaw S. C., Murday V. A., Tomlinson I. P., Thomas H. J., Cottrell S., Ginsberg A., Bukofzer S., Hodgson S. V., Skudowitz R. B., Jass J. R. Clinical and molecular features of the hereditary mixed polyposis syndrome. Gastroenterology. 1997 Feb;112(2):327–334. doi: 10.1053/gast.1997.v112.pm9024286. [DOI] [PubMed] [Google Scholar]
  118. Wildrick D. M., Alfaro S. R., Gope R., Boman B. M. A study of chromosome 6 allele loss in human colorectal carcinomas. Anticancer Res. 1992 Sep-Oct;12(5):1717–1719. [PubMed] [Google Scholar]
  119. Yamaguchi A., Kurosaka Y., Fushida S., Kanno M., Yonemura Y., Miwa K., Miyazaki I. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer. 1992 Dec 15;70(12):2778–2784. doi: 10.1002/1097-0142(19921215)70:12<2778::aid-cncr2820701209>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  120. Yana I., Kurahashi H., Nakamori S., Kameyama M., Nakamura T., Takami M., Mori T., Takai S., Nishisho I. Frequent loss of heterozygosity at telomeric loci on 22q in sporadic colorectal cancers. Int J Cancer. 1995 Jan 17;60(2):174–177. doi: 10.1002/ijc.2910600207. [DOI] [PubMed] [Google Scholar]
  121. Young J., Leggett B., Gustafson C., Ward M., Searle J., Thomas L., Buttenshaw R., Chenevix-Trench G. Genomic instability occurs in colorectal carcinomas but not in adenomas. Hum Mutat. 1993;2(5):351–354. doi: 10.1002/humu.1380020505. [DOI] [PubMed] [Google Scholar]
  122. Young J., Leggett B., Ward M., Thomas L., Buttenshaw R., Searle J., Chenevix-Trench G. Frequent loss of heterozygosity on chromosome 14 occurs in advanced colorectal carcinomas. Oncogene. 1993 Mar;8(3):671–675. [PubMed] [Google Scholar]
  123. Zeng Z. S., Sarkis A. S., Zhang Z. F., Klimstra D. S., Charytonowicz E., Guillem J. G., Cordon-Cardo C., Cohen A. M. p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. J Clin Oncol. 1994 Oct;12(10):2043–2050. doi: 10.1200/JCO.1994.12.10.2043. [DOI] [PubMed] [Google Scholar]
  124. de Bruin P. A., Griffioen G., Verspaget H. W., Verheijen J. H., Dooijewaard G., van den Ingh H. F., Lamers C. B. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res. 1988 Aug 15;48(16):4520–4524. [PubMed] [Google Scholar]

Articles from Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES